☆ 4.6 Article

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study

PEERJ (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Suboptimal Performance of Hepatocellular Carcinoma Prediction Models in Patients with Hepatitis B Virus-Related Cirrhosis

Jae Seung Lee et al.

Summary: This study evaluated the predictive performance of pre-existing well-validated hepatocellular carcinoma (HCC) prediction models in patients with HBV-related cirrhosis who started potent antiviral therapy (AVT). The results showed that the existing risk prediction models for patients with chronic hepatitis B had suboptimal predictive performances for assessing HCC development in patients with HBV-related cirrhosis. Although the models were not highly accurate, they were still able to stratify patients into low-, intermediate-, or high-risk groups.

DIAGNOSTICS (2023)

Add to Collection

Article Gastroenterology & Hepatology

On-treatment gamma-glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients

Chung-Feng Huang et al.

Summary: The study found that in CHB patients, measuring serum GGT levels during treatment, particularly in non-cirrhotic patients, can effectively predict the development of HCC. Factors strongly associated with increased risk of HCC included high M6-GGT levels, age, gender, and cirrhosis.

LIVER INTERNATIONAL (2022)

Add to Collection

Article Gastroenterology & Hepatology

The best predictive model for hepatocellular carci-noma in patients with chronic hepatitis B infection

Jung Hwan Yu et al.

Summary: Chronic hepatitis B is a serious threat to human health, causing a large number of deaths from complications such as hepatitis B and hepatocellular carcinoma (HCC). While the use of oral antiviral agents has improved the prognosis and reduced the risk of HCC in patients with CHB, the hepatitis B virus remains a major factor in HCC development. Therefore, numerous studies have been conducted to assess the risk of HCC in CHB patients and predict its development using different models. Understanding the characteristics and variables used in each model is essential for accurate evaluation.

CLINICAL AND MOLECULAR HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma

Grace L. Su et al.

Summary: This article presents the research and recommendations for systemic therapies for HCC, providing evidence-based guidelines for patients.

GASTROENTEROLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Emerging immunotherapy or HCC: A guide for hepatologists

Friedrich Foerster et al.

Summary: HCC is one of the most common and deadliest cancers globally. Immuno-oncology has shown promising results in the treatment of HCC, with immune checkpoint inhibition becoming the first-line therapy for advanced cases. However, challenges remain in determining the role of immunotherapy in earlier stages of HCC and identifying treatment strategies for non-responsive patients.

HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease

Won Sohn et al.

Summary: This study investigated the effect of HCC surveillance using the Korea National Liver Cancer Screening Program on the treatment and mortality of patients with chronic liver disease. The results showed that patients who underwent surveillance had a higher proportion of curative treatment for HCC and a lower mortality rate.

CLINICAL AND MOLECULAR HEPATOLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin et al.

Summary: This review comprehensively summarizes the relationship between metabolic factors such as diabetes mellitus, obesity, and blood lipids and the risk of hepatocellular carcinoma (HCC) in patients with chronic liver diseases. Diabetes consistently increases the risk of HCC in patients with chronic liver disease, while obesity may also increase the risk. In terms of blood lipids, total cholesterol, low-density lipoprotein cholesterol, and triglyceride have strong inverse associations with HCC in individuals with chronic liver diseases.

CLINICAL AND MOLECULAR HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients

Hye Yeon Chon et al.

Summary: The study compared the effects of three antiviral agents on the risk of hepatocellular carcinoma and orthotopic liver transplantation or mortality in patients with chronic hepatitis B. It was found that the outcomes of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide were statistically similar in treatment-naive patients with CHB.

HEPATOLOGY INTERNATIONAL (2021)

Add to Collection

Article Oncology

Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy

Jae Seung Lee et al.

Summary: A novel risk-scoring model for predicting hepatocellular carcinoma development in treatment-naive patients with chronic hepatitis B virus infection starting antiviral therapy has been developed, showing better performance in Asian patients. This model is important for developing individualized surveillance methods.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal

External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy

Honglian Gui et al.

Summary: The study validated the aMAP score for predicting HCC risk in patients with compensated cirrhosis and found that combining aMAP score with diabetes status can further stratify the risk of HCC. The predictive performance of aMAP at 1 year after antiviral therapy initiation was better than at enrollment.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis

Sung Won Lee et al.

GUT (2020)

Add to Collection

Article Oncology

Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B:A Multicenter Study

Seung Up Kim et al.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)

Add to Collection

Article Gastroenterology & Hepatology

Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog

Sakura Kirino et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis

Ingyoon Ha et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Rong Fan et al.

JOURNAL OF HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Risk of Hepatocellular Carcinoma Remains High in Patients with HBV-Related Decompensated Cirrhosis and Long-Term Antiviral Therapy

Dong-Mei Zhu et al.

CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals

Andrea Casadei Gardini et al.

DIGESTIVE AND LIVER DISEASE (2019)

Add to Collection

Article Gastroenterology & Hepatology

A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea

Seung Up Kim et al.

JOURNAL OF HEPATOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

External validation of the modified PAGE-B score in Asian chronic hepatitis B patients receiving antiviral therapy

Hye Won Lee et al.

LIVER INTERNATIONAL (2019)

Add to Collection

Article Gastroenterology & Hepatology

New concepts on the clinical course and stratification of compensated and decompensated cirrhosis

Gennaro D'Amico et al.

HEPATOLOGY INTERNATIONAL (2018)

Add to Collection

Article Gastroenterology & Hepatology

Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B

Yao-Chun Hsu et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy

Ji Hyun Kim et al.

JOURNAL OF HEPATOLOGY (2018)

Add to Collection

Article Gastroenterology & Hepatology

PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

George Papatheodoridis et al.

JOURNAL OF HEPATOLOGY (2016)

Add to Collection

Article Oncology

Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score

Hwai-I Yang et al.

LANCET ONCOLOGY (2011)

Add to Collection

Review Gastroenterology & Hepatology

Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies

G D'Amico et al.

JOURNAL OF HEPATOLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.